Drugs / Adalimumab
Regulatory milestones approvals, filings & regulatory actions · 31 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | HADLIMA | — | 2022-06-17 – 2023-07-11 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | HYRIMOZ | — | 2022-07-18 – 2023-03-20 | fda.gov ↗ |
| Label expansion | US (FDA) | HULIO | — | 2022-07-14 | fda.gov ↗ |
| Label expansions (22) | US (FDA) | HUMIRA | — | 2004-07-30 – 2021-02-24 | fda.gov ↗ |
| Approved | EU (EMA) | Trudexa | — | 2003-09-01 | europa.eu ↗ |
| Approved | US (FDA) | HUMIRA | — | 2002-12-31 | fda.gov ↗ |
Trials 296 · started per year
today
US approved 2002
EU approved 2003
4
6
9
11
7
19
15
14
13
14
14
14
11
13
16
9
7
4
10
11
13
12
8
12
10
15
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06742606 | Jan 2025 → Apr 2026 overdue | — | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 116 trials | ||||||
| Phase 1 | NCT06926478 | Jun 2026 → Jun 2027 expected | Stevens-Johnson syndrome, ocular cicatricial pemphigoid | Massachusetts Eye and Ear Infirmary | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07181694 | Mar → Nov 2025 overdue | — | Biocad | Recruiting | No outcome recorded |
| Phase 1 | NCT05884242 | May → Aug 2023 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05909852 | Jul → Nov 2021 | — | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT04514796 | Aug 2020 → May 2021 | — | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04439929 | Jul 2019 → Jan 2020 | — | Turgut İlaçları A.Ş. | Completed | No outcome recorded |
| Phase 1 | NCT03983876 | Jul → Dec 2019 | — | Alvotech Swiss AG | Completed | No outcome recorded |
| Phase 1 | NCT03849313 | Mar 2019 → Feb 2020 | — | Alvotech Swiss AG | Completed | No outcome recorded |
| Phase 1 | NCT03579823 | May → Aug 2018 | — | Alvotech Swiss AG | Completed | No outcome recorded |
| Phase 1 | NCT03273192 | Oct 2016 → Aug 2017 | — | Cinnagen | Completed | No outcome recorded |
| Phase 1 | NCT02395055 | Jun → Oct 2015 | — | Biocad | Completed | No outcome recorded |
| Phase 1 | NCT02326233 | Jun → Sep 2015 | — | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02516774 | Dec 2014 → Dec 2015 | thyroid gland undifferentiated (anaplastic) carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Withdrawn | No outcome recorded |
| Phase 1 | NCT00855608 | Mar 2009 → Mar 2013 | choroidal neovascularization, diabetic retinopathy, uveitis | Rafic Hariri University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT00650156 | Jun → Oct 2007 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT00421642 | Oct 2006 → Apr 2008 | ulcerative colitis | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT07061574 | Mar 2026 → Apr 2030 expected | type 1 diabetes mellitus | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07258641 | Jan 2026 → Dec 2027 expected | Crohn disease, ulcerative colitis | University Medical Center Groningen | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07348588 | Jul → Aug 2025 overdue | retinitis pigmentosa | Centro de Pesquisa Rubens Siqueira | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02586831 | Jun 2024 | hypoglycemia, type 1 diabetes mellitus | Camillo Ricordi and Jay Skyler | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03607903 | Jul → Oct 2018 | — | Centre for Human Drug Research, Netherlands | Completed | No outcome recorded |
| Phase 1/2 | NCT03153319 | Jun 2017 → Jan 2027 expected | mucopolysaccharidosis type 1, mucopolysaccharidosis type 2, mucopolysaccharidosis type 6 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02437253 | May 2015 → Jul 2016 | mucopolysaccharidosis type 1, mucopolysaccharidosis type 2, mucopolysaccharidosis type 6 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01275508 | Jan 2011 → Apr 2012 | Crohn disease | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 1/2 | NCT00686439 | Jun 2008 → Nov 2010 | osteoarthritis | University of Alberta | Completed | No outcome recorded |
| Phase 246 trials | ||||||
| Phase 2 | NCT06996652 | Jun 2026 → Aug 2029 expected | REM sleep behavior disorder | Yale University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07268534 | Apr 2026 → Nov 2029 expected | Quinquaud's folliculitis decalvans | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT07208539 | Oct 2025 → Apr 2026 overdue | malignant pancreatic neoplasm | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07137858 | Aug 2025 → Jun 2027 expected | oral cavity squamous cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06941376 | Aug 2025 → Jul 2027 expected | relapsing polychondritis | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2 | NCT06849908 | Nov 2024 → Jun 2027 expected | Behcet disease | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT03938701 | Aug 2024 → Mar 2026 overdue | inflammatory bowel disease, rheumatoid arthritis | University Medical Center Groningen | Recruiting | No outcome recorded |
| Phase 2 | NCT06257875 | Mar 2024 → Sep 2027 expected | ulcerative colitis | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05874505 | Jul 2023 → Nov 2026 expected | uveitis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05590455 | Apr 2023 → Jun 2027 expected | HIV infectious disease, meningeal tuberculosis | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 2 | NCT05155592 | Jan 2021 → Jan 2023 | uveitis | Dan Liang | Unknown | No outcome recorded |
| Phase 2 | NCT03651518 | Oct 2020 → Nov 2025 | autoimmune disease, inflammatory disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT04588818 | Feb 2020 → Dec 2023 | uveitis | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03823391 | Mar 2019 → Apr 2020 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT03180957 | Mar 2016 → Nov 2020 | palmar fibromatosis | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT02565810 | Sep 2015 → Mar 2016 | rheumatoid arthritis | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02393378 | Apr 2015 → Jun 2016 | rheumatoid arthritis | Takeda | Terminated | No outcome recorded |
| Phase 2 | NCT02471118 | Mar 2015 → Mar 2021 | osteoarthritis, knee | CARE ARTHRITIS LTD. | Completed | No outcome recorded |
| Phase 2 | NCT02113904 | Jan 2014 → Dec 2016 | Netherton syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT02015793 | Dec 2013 → Feb 2015 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01872546 | Jan → Apr 2013 | psoriasis | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01752855 | Dec 2012 → Oct 2013 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01561313 | Mar → Nov 2012 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01502423 | Jan → Nov 2012 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01373151 | Jun 2011 → Sep 2012 | rheumatoid arthritis | CSL Behring | Completed | No outcome recorded |
| Phase 2 | NCT04154852 | Jun 2011 → Jan 2017 | arthritic joint disease | University of Leeds | Completed | No outcome recorded |
| Phase 2 | NCT01136252 | May 2010 → Sep 2011 | age-related macular degeneration, choroidal neovascularization | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02456363 | Nov 2009 → Oct 2019 | ankylosing spondylitis | Chung Shan Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT00731757 | May 2009 → Dec 2010 | skin sarcoidosis | Wright State University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00730717 | May 2009 → Dec 2010 | pyoderma gangrenosum | Wright State University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00918255 | Apr 2009 → Mar 2010 | hidradenitis suppurativa | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00814255 | Dec 2008 → Jun 2013 | focal segmental glomerulosclerosis | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT00525902 | Jan 2008 → Sep 2010 | uveitis | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2 | NCT00514982 | Aug 2007 → Mar 2011 | Hermansky-Pudlak syndrome, colitis | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 2 | NCT00512863 | Aug 2007 → ? | asthma | Abbott | Withdrawn | No outcome recorded |
| Phase 2 | NCT00690846 | Jul 2007 | pyoderma gangrenosum | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2 | NCT00827996 | Feb → Nov 2007 | hidradenitis suppurativa | Florida Academic Dermatology Centers | Completed | No outcome recorded |
| Phase 2 | NCT00274352 | Sep 2006 → Feb 2012 | skin sarcoidosis | Pariser, Robert J., M.D. | Completed | No outcome recorded |
| Phase 2 | NCT00296894 | May 2006 → Jan 2009 | arthropathy, erosive | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 2 | NCT00311246 | Apr 2006 → May 2008 | sarcoidosis | University of Chicago | Terminated | No outcome recorded |
| Phase 2 | NCT00185562 | Jun 2005 → Jan 2006 | osteoarthritis | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00470509 | May 2005 → Jan 2008 | sciatica | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 2 | NCT00235833 | Jun 2003 → Oct 2004 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00055523 | Apr 2002 → ? | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00690911 | — | sarcoidosis | Wake Forest University | Withdrawn | No outcome recorded |
| Phase 2/311 trials | ||||||
| Phase 2/3 | NCT05535738 | Nov 2022 → Jan 2027 expected | allergic contact dermatitis | Wei-Che Ko | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05172817 | Jun → Nov 2021 | rheumatoid arthritis | Institute for Developing Science and Health Initiatives, Bangladesh | Unknown | No outcome recorded |
| Phase 2/3 | NCT01385826 | Jun 2011 → Nov 2014 | juvenile idiopathic arthritis, uveitis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2/3 | NCT00538902 | Aug 2007 → Jul 2008 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 2/3 | NCT00445432 | Mar 2007 → Mar 2009 | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 2/3 | NCT00445939 | Feb → Dec 2007 | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 2/3 | NCT00348153 | Aug 2006 → Sep 2012 | uveitis | Heidelberg University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00647400 | Apr 2006 → Sep 2007 | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 2/3 | NCT00338754 | Nov 2005 → ? | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 2/3 | NCT00235105 | Mar 2005 → Jun 2007 | ankylosing spondylitis | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 2/3 | NCT00647491 | Feb 2004 → Jun 2005 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3106 trials | ||||||
| Phase 3 | NCT06654882 | Jan → Dec 2026 expected | polyarticular juvenile idiopathic arthritis | Duke University | Recruiting | No outcome recorded |
| Phase 3 | NCT06100744 | Jul 2024 → Sep 2026 expected | psoriasis-related juvenile idiopathic arthritis | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT06258915 | Mar 2024 → Jun 2027 expected | uveitis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05814627 | Jun 2023 → Jul 2026 overdue | rheumatoid arthritis | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05379322 | Mar 2023 | rheumatoid arthritis | Abu Dhabi Stem Cells Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT05637515 | Nov 2022 → Sep 2023 | psoriasis | Biocon Biologics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05495568 | Nov 2022 → Aug 2023 | psoriasis | Celltrion | Completed | No outcome recorded |
| Phase 3 | NCT04798755 | Jan 2022 → Oct 2024 | uveitis | Hospital San Carlos, Madrid | Unknown | No outcome recorded |
| Phase 3 | NCT05073315 | Oct 2021 → Dec 2022 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT04909801 | Sep 2021 → Jun 2023 overdue | rheumatoid arthritis | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04705844 | Sep 2021 → Sep 2022 | — | Alachua Government Services, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04870203 | Jul 2021 → Mar 2027 expected | rheumatoid arthritis | University Hospital, Bordeaux | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04610476 | Oct 2020 → Oct 2024 | psoriatic arthritis, substance withdrawal syndrome | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT04453137 | Jun 2020 → May 2021 | psoriasis | Alvotech Swiss AG | Completed | No outcome recorded |
| Phase 3 | NCT04230213 | Jan 2020 → Jun 2021 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04224194 | Nov 2019 → Jul 2020 | rheumatoid arthritis | Alvotech Swiss AG | Completed | No outcome recorded |
| Phase 3 | NCT04171414 | Sep → Nov 2019 | rheumatoid arthritis | Celltrion | Completed | No outcome recorded |
| Phase 3 | NCT03849404 | Feb → Dec 2019 | psoriasis | Alvotech Swiss AG | Completed | No outcome recorded |
| Phase 3 | NCT03311464 | Oct 2017 → Aug 2019 | pyoderma gangrenosum | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02840175 | May 2017 → Oct 2019 | juvenile idiopathic arthritis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT03104400 | Apr 2017 → Sep 2019 | psoriatic arthritis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02904902 | Sep 2016 → Sep 2017 | hidradenitis suppurativa | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02660580 | Feb → Dec 2016 | psoriasis | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02629159 | Dec 2015 → Oct 2017 overdue | rheumatoid arthritis | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02632175 | Nov 2015 → Apr 2025 | ulcerative colitis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03172325 | Nov 2015 → Aug 2016 | rheumatoid arthritis | Cinnagen | Completed | No outcome recorded |
| Phase 3 | NCT02533375 | Sep 2015 → Sep 2016 | generalized pustular psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02581345 | Sep 2015 → Apr 2017 | psoriasis | Momenta Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02499783 | Aug 2015 → May 2017 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02065557 | Oct 2014 → Feb 2020 | ulcerative colitis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02150473 | Oct 2014 → Sep 2017 | rheumatoid arthritis | Heinrich-Heine University, Duesseldorf | Terminated | No outcome recorded |
| Phase 3 | NCT02185014 | Aug 2014 → Nov 2017 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02196701 | Aug 2014 → Mar 2017 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02065570 | May 2014 → Jan 2020 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02167139 | May 2014 → Apr 2015 | rheumatoid arthritis | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02019472 | Apr 2014 → Aug 2016 | rheumatoid arthritis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02114931 | Apr 2014 → Apr 2016 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT02065622 | Mar 2014 → Sep 2019 | ulcerative colitis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01986127 | Feb 2014 → Jun 2018 | Crohn disease | Sara Varea | Terminated | No outcome recorded |
| Phase 3 | NCT01970488 | Oct 2013 → Aug 2014 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01958827 | Sep 2013 → Mar 2015 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01497717 | Jul 2013 → Oct 2016 | Behcet syndrome arthropathy | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 3 | NCT01808118 | Apr 2013 → Feb 2017 | spondyloarthropathy | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01646073 | Aug 2012 → Dec 2013 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01629628 | Jul 2012 → Jul 2016 | Crohn disease | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01550965 | May 2012 → Apr 2015 | ulcerative colitis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01635764 | Apr 2012 → Aug 2016 | hidradenitis suppurativa | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01494857 | Jan 2012 → Dec 2013 | ulcerative colitis | Clalit Health Services | Unknown | No outcome recorded |
| Phase 3 | NCT01468207 | Nov 2011 → Jan 2014 | hidradenitis suppurativa | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01468233 | Nov 2011 → Apr 2014 | hidradenitis suppurativa | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01295814 | Mar 2011 → Jun 2013 | interstitial cystitis | ICStudy, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01235689 | Feb 2011 → Nov 2016 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01251614 | Dec 2010 → Dec 2013 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01148225 | Nov 2010 → May 2018 | uveitis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01243671 | Oct 2010 → Mar 2012 | Behcet disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01166282 | Sep 2010 → Nov 2012 | enthesitis-related juvenile idiopathic arthritis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01124838 | Aug 2010 → May 2015 | uveitis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01138657 | Aug 2010 → Jul 2014 | uveitis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01064856 | Feb 2010 → Aug 2011 | spondyloarthropathy | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01114880 | Jan → Sep 2010 | ankylosing spondylitis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00939003 | Jul 2009 → Feb 2011 | spondyloarthropathy | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00775437 | Mar 2009 → Mar 2013 | juvenile idiopathic arthritis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00870467 | Mar 2009 → Mar 2011 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00853099 | Feb 2009 → May 2011 | ulcerative colitis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02779114 | Jan 2009 → Dec 2017 | rheumatoid arthritis | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT00686374 | May 2008 → Apr 2017 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00690573 | May 2008 → Mar 2010 | juvenile idiopathic arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00667355 | Feb 2008 → May 2009 | ankylosing spondylitis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00566722 | Jan 2008 → Apr 2009 | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT01231321 | Dec 2007 → Feb 2010 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00573794 | Nov 2007 → Dec 2016 | ulcerative colitis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00660647 | Sep 2007 → Dec 2011 | rheumatoid arthritis | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT00513370 | Sep 2007 → Sep 2008 | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00927069 | Mar 2007 → Sep 2008 | psoriasis | Innovaderm Research Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00427921 | Jan 2007 → Jan 2008 | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00409617 | Dec 2006 → Jul 2008 | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00385736 | Nov 2006 → Apr 2009 | ulcerative colitis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00408629 | Nov 2006 → Mar 2010 | ulcerative colitis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00348283 | Aug 2006 → Sep 2008 | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00338650 | Jun 2006 → May 2007 | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00427362 | May 2006 → May 2007 | psoriatic arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00603993 | Mar → Nov 2006 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00478660 | Feb 2006 → ? | ankylosing spondylitis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00235885 | Jul 2005 → ? | psoriatic arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00237887 | Dec 2004 → ? | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00105300 | Oct 2004 → ? | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00195715 | Sep 2004 → Mar 2006 | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00235872 | Aug 2004 → Jul 2006 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00195676 | May 2004 → Oct 2009 | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00085644 | Jan → Dec 2004 | ankylosing spondylitis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00234936 | Dec 2003 → ? | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00195819 | Dec 2003 → Oct 2004 | ankylosing spondylitis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00195689 | Aug 2003 → ? | psoriatic arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00647920 | Jul 2003 → Apr 2005 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00077779 | Jul 2003 → ? | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00235859 | Jul 2003 → ? | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00234845 | Mar 2003 → ? | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00448383 | Sep 2002 → Nov 2004 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00049751 | Sep 2002 → ? | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00048542 | Sep 2002 → Jan 2005 | polyarticular juvenile idiopathic arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00055497 | Aug 2002 → Jan 2005 | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT01070303 | Aug 2002 → Dec 2008 | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00195663 | Dec 2000 → Apr 2004 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00195650 | Jul 2000 → May 2011 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00233571 | Jun 2000 → Jun 2006 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00195702 | Feb 2000 → Sep 2002 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 493 trials | ||||||
| Phase 4 | NCT06390436 | Dec 2026 → Dec 2029 expected | uveitis | University Hospital of Saint-Etienne | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07699107 | Sep 2026 → May 2030 expected | anterior uveitis, juvenile idiopathic arthritis | Nisha Acharya | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07663526 | Aug 2026 → Dec 2028 expected | Crohn disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07663331 | Jul 2026 → Feb 2028 expected | uveitis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 4 | NCT07529925 | May 2026 → Apr 2028 expected | psoriasis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07564505 | May 2026 → Mar 2029 expected | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07510191 | Mar 2026 → Dec 2028 expected | Crohn disease | Sixth Affiliated Hospital, Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 4 | NCT07149792 | Jul 2025 → Dec 2026 expected | psoriasis, psoriatic arthritis | Taichung Veterans General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06833112 | Feb 2025 → Aug 2027 expected | ankylosing spondylitis | The Affiliated Hospital Of Guizhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06528431 | Dec 2024 → Sep 2026 expected | rheumatoid arthritis | University Hospital of Saint-Etienne | Recruiting | No outcome recorded |
| Phase 4 | NCT06180382 | Oct 2024 → Oct 2027 expected | Crohn disease | University Hospital of Saint-Etienne | Recruiting | No outcome recorded |
| Phase 4 | NCT06440629 | Aug 2024 → Dec 2027 expected | rheumatoid arthritis | Diakonhjemmet Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06498089 | Jun 2024 → Jun 2026 overdue | Takayasu arteritis | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06045754 | Apr 2024 → Jun 2027 expected | Crohn disease | Takeda | Recruiting | No outcome recorded |
| Phase 4 | NCT05781152 | Jun 2023 → Jul 2028 expected | Crohn disease | Connecticut Children's Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05169593 | Sep 2022 → Oct 2027 expected | Crohn disease | Universitaire Ziekenhuizen KU Leuven | Recruiting | No outcome recorded |
| Phase 4 | NCT05510063 | Aug 2022 → Apr 2023 | psoriasis | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT05414201 | Jul 2022 → Jun 2024 | uveitis | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT05540743 | Jul 2022 → Dec 2023 | unspecified juvenile idiopathic arthritis | Kasr El Aini Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05527444 | Mar 2022 → Dec 2024 | ankylosing spondylitis | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT05164198 | Jan 2022 → Oct 2024 | ankylosing spondylitis | Hanyang University Seoul Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05151848 | Jan 2022 → Jan 2026 | Takayasu arteritis | Chinese SLE Treatment And Research Group | Unknown | No outcome recorded |
| Phase 4 | NCT05626348 | Dec 2021 → Jun 2025 overdue | rheumatoid arthritis | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 4 | NCT05115903 | Dec 2021 → Jul 2024 | spondyloarthropathy | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT05080218 | Nov 2021 → Apr 2024 | psoriatic arthritis, spondyloarthropathy | Jeffrey Curtis | Completed | No outcome recorded |
| Phase 4 | NCT05015335 | Aug 2021 → Jul 2022 | non-infectious anterior uveitis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04646187 | Mar 2021 → Mar 2026 overdue | Crohn disease, ulcerative colitis | University Medical Center Groningen | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04028713 | Feb 2021 → Mar 2022 | psoriasis | University Hospital, Ghent | Terminated | No outcome recorded |
| Phase 4 | NCT04132388 | Aug 2020 → Sep 2022 | hidradenitis suppurativa | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 4 | NCT04194827 | Mar 2020 → Dec 2024 | rheumatoid arthritis | Reade Rheumatology Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT04222920 | Mar 2020 → Sep 2023 | rheumatoid arthritis | Reade Rheumatology Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT04300686 | Mar 2020 → May 2022 overdue | Takayasu arteritis | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04131322 | Oct 2019 → Jun 2020 | Crohn disease, ulcerative colitis | Andalusian Public Foundation for Health Research in Seville | Terminated | No outcome recorded |
| Phase 4 | NCT04045782 | Aug 2019 → Jan 2021 | inflammatory bowel disease | Pieter Dewint, MD PhD | Completed | No outcome recorded |
| Phase 4 | NCT03739853 | May 2019 → Oct 2024 | psoriatic arthritis | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT03221621 | Jul 2018 → Jul 2022 | hidradenitis suppurativa | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT03505008 | Apr 2018 → May 2021 | rheumatoid arthritis | Keio University | Completed | No outcome recorded |
| Phase 4 | NCT03220841 | Oct 2017 → Sep 2020 | Crohn disease, intestinal obstruction | St Vincent's Hospital Melbourne | Unknown | No outcome recorded |
| Phase 4 | NCT02764762 | Apr 2017 → Sep 2020 | Crohn disease | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT02852694 | Feb 2017 → Jun 2021 | Crohn disease | PIBD-Net | Completed | No outcome recorded |
| Phase 4 | NCT02897115 | Sep 2016 → Dec 2017 | spondyloarthropathy | AbbVie | Terminated | No outcome recorded |
| Phase 4 | NCT02814175 | Aug 2016 → Sep 2019 | psoriatic arthritis | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT02714634 | Mar 2016 → Mar 2029 expected | rheumatoid arthritis | University Hospital, Strasbourg, France | Recruiting | No outcome recorded |
| Phase 4 | NCT02878161 | Jan 2016 → Dec 2019 | rheumatoid arthritis | Fen Li | Unknown | No outcome recorded |
| Phase 4 | NCT02634541 | Jan 2016 → Dec 2017 | ankylosing spondylitis | University of Helsinki | Unknown | No outcome recorded |
| Phase 4 | NCT02256462 | May 2015 → Jan 2019 | Crohn disease | Schneider Children's Medical Center, Israel | Completed | No outcome recorded |
| Phase 4 | NCT02492217 | May 2015 → May 2018 | ankylosing spondylitis | NOVA University Lisbon | Completed | No outcome recorded |
| Phase 4 | NCT03306446 | Mar 2015 → Mar 2021 | — | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Unknown | No outcome recorded |
| Phase 4 | NCT02198651 | Jan 2015 → May 2018 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT02148718 | Jun 2014 → Aug 2016 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT01893996 | Jul 2013 → Jul 2017 | cardiovascular disorder, rheumatoid arthritis | Jonathan Graf | Completed | No outcome recorded |
| Phase 4 | NCT02132234 | Jun 2013 → Jul 2014 | ankylosing spondylitis, hypertensive disorder, psoriatic arthritis | Jagiellonian University | Unknown | No outcome recorded |
| Phase 4 | NCT02035800 | May 2013 → Dec 2018 | rheumatoid arthritis | University of Sherbrooke | Unknown | No outcome recorded |
| Phase 4 | NCT01866592 | Apr 2013 → Aug 2016 | cardiovascular disorder, psoriasis | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT01895764 | Mar 2013 → Apr 2015 | ankylosing spondylitis | University Hospital, Tours | Completed | No outcome recorded |
| Phase 4 | NCT01722214 | Nov 2012 → Dec 2015 | coronary atherosclerosis, psoriasis | Innovaderm Research Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01609205 | Oct 2012 → Sep 2017 | rheumatoid arthritis | Hamed Rezaei | Completed | No outcome recorded |
| Phase 4 | NCT01604629 | Jul 2012 → Apr 2015 | spondyloarthropathy | Spanish Clinical Pharmacology Society | Completed | No outcome recorded |
| Phase 4 | NCT01602302 | Jun 2012 → Nov 2020 | rheumatoid arthritis | Medical University of Graz | Terminated | No outcome recorded |
| Phase 4 | NCT01644396 | May 2012 → Sep 2013 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT01556672 | Apr 2012 → Jan 2016 | Crohn disease, psoriasis | Innovaderm Research Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01548768 | Oct 2011 → Sep 2019 | rheumatoid arthritis | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT01295151 | Aug 2011 → Nov 2015 | rheumatoid arthritis | Julia Brown | Completed | No outcome recorded |
| Phase 4 | NCT01405326 | May 2011 → Dec 2012 | rheumatoid arthritis | The Rheumatological Center of Helsinki | Unknown | No outcome recorded |
| Phase 4 | NCT01382160 | Jan 2011 → Jul 2013 | rheumatoid arthritis | University Hospital, Tours | Completed | No outcome recorded |
| Phase 4 | NCT01270035 | Jan 2011 → Jan 2014 | rheumatoid arthritis | Keio University | Unknown | No outcome recorded |
| Phase 4 | NCT01265823 | Oct 2010 → Feb 2012 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT01162421 | Sep 2010 → Jul 2015 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT01181570 | Sep 2010 → Aug 2011 | obstructive sleep apnea syndrome, psoriasis | Innovaderm Research Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01185288 | Sep 2010 → Jan 2013 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT01088165 | May 2010 → May 2013 | cardiovascular disorder, psoriasis, type 2 diabetes mellitus | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT00940862 | Jul 2009 → Jun 2011 | coronary atherosclerosis, psoriasis | Innovaderm Research Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00972218 | Jul 2009 → Jan 2010 | Crohn disease, spondyloarthropathy | University of Alberta | Withdrawn | No outcome recorded |
| Phase 4 | NCT00837434 | Mar 2009 → Nov 2013 | rheumatoid arthritis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT00796705 | Nov 2008 → Oct 2010 | rheumatoid arthritis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 4 | NCT00780793 | Sep 2008 → Sep 2011 | rheumatoid arthritis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT02489760 | Jul 2008 → Dec 2015 | ankylosing spondylitis | Chung Shan Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT00726804 | Mar 2008 → May 2012 | spondyloarthropathy | Glostrup University Hospital, Copenhagen | Terminated | No outcome recorded |
| Phase 4 | NCT01072058 | Feb 2008 → Feb 2011 | ankylosing spondylitis | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT00517296 | Jan 2008 → Dec 2014 | Crohn disease, anal fistula | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00480272 | May 2007 → Mar 2017 | rheumatoid arthritis | Fondazione IRCCS Policlinico San Matteo di Pavia | Completed | No outcome recorded |
| Phase 4 | NCT00420927 | Dec 2006 → Jul 2010 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT00761514 | Nov 2006 → Aug 2008 | rheumatoid arthritis | Abbott | Terminated | No outcome recorded |
| Phase 4 | NCT01465438 | Nov 2006 → Jun 2011 | psoriatic arthritis | Glostrup University Hospital, Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT00234234 | Jan 2006 → Dec 2008 | rheumatoid arthritis | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 4 | NCT00216177 | Sep 2005 → Jan 2009 | rheumatoid arthritis | Hvidovre University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01270087 | May 2005 → Feb 2007 | rheumatoid arthritis | Skane University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00133315 | Sep 2004 → Apr 2007 | ankylosing spondylitis, psoriatic arthritis | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00234897 | Aug 2004 → ? | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT00696059 | Aug 2004 → Jul 2007 | rheumatoid arthritis | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00291915 | May 2004 → Mar 2007 | rheumatoid arthritis | Goupe d'Etudes et de Recherche Clinique En Rhumatologie | Unknown | No outcome recorded |
| Phase 4 | NCT00649922 | Oct 2003 → Dec 2004 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07398651 | Dec 2026 expected | psoriatic arthritis | Tanta University | Not yet recruiting | No outcome recorded |
| — | NCT07491913 | Jun 2025 → Dec 2027 expected | Takayasu arteritis | Marmara University | Recruiting | No outcome recorded |
| — | NCT06310837 | Mar 2024 → Oct 2025 overdue | uveitis | Zhongshan Ophthalmic Center, Sun Yat-sen University | Active not recruiting | No outcome recorded |
| — | NCT05305066 | Feb 2023 → Dec 2028 expected | rheumatoid arthritis | Marie Hudson, MD | Recruiting | No outcome recorded |
| — | NCT05503875 | Jan 2023 → Dec 2027 expected | psoriasis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT05090124 | Nov 2022 → Nov 2024 | rheumatoid arthritis | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| — | NCT04378621 | Oct 2020 → Sep 2025 | depressive disorder, rheumatoid arthritis, subjective cognitive decline | Vastra Gotaland Region | Unknown | No outcome recorded |
| — | NCT01320293 | Mar 2011 → Mar 2015 | psoriasis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT00814866 | Sep 2008 → Sep 2010 | rheumatoid arthritis | University of Sherbrooke | Completed | No outcome recorded |
| — | NCT00497614 | May 2006 → Dec 2007 | rheumatoid arthritis | University Hospital, Tours | Completed | No outcome recorded |
| — | NCT01144156 | — | small bowel Crohn disease | Rabin Medical Center | Unknown | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT00650390 | — | rheumatoid arthritis | Abbott | Approved for marketing | No outcome recorded |
| — | NCT00649545 | — | rheumatoid arthritis | Abbott | Approved for marketing | No outcome recorded |
| — | NCT00650026 | — | rheumatoid arthritis | Abbott | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 190 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02252809 Comparator | Nov 2008 → Apr 2009 | — | Brugmann University Hospital | Completed | No outcome recorded |
| Phase 117 trials | ||||||
| Phase 1 | NCT07147257 Comparator | Feb → May 2025 | — | Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06291948 Comparator | Aug 2022 → Jan 2023 | — | Laboratorios Richmond S.A.C.I.F. | Completed | No outcome recorded |
| Phase 1 | NCT05108259 Comparator | Mar 2022 → Feb 2026 overdue | — | Prestige Biopharma Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT04551352 Background | Oct 2020 → Jul 2022 | cutaneous melanoma, mucosal melanoma, uveal melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03970824 Comparator | May → Nov 2019 | — | Celltrion | Completed | No outcome recorded |
| Phase 1 | NCT03917628 Comparator | May → Nov 2019 | — | Sinocelltech Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03254810 Comparator | Sep 2017 → Jul 2018 | rheumatoid arthritis | Synermore Biologics Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03357939 Comparator | Jan 2017 → Sep 2018 | immune system disorder | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 1 | NCT02237729 Comparator | Sep 2014 → Mar 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02206867 Comparator | Aug 2014 → Feb 2015 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02144714 Comparator | May → Sep 2014 | — | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03014947 Comparator | May → Dec 2014 | — | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02045979 Comparator | Jan → Jun 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01899755 Comparator | Jul 2013 → Apr 2014 | psoriasis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01870986 Comparator | May 2013 → Feb 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01505491 Comparator | Dec 2011 → Jul 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00193648 Comparator | Jul 2005 → Oct 2007 | focal segmental glomerulosclerosis | Northwell Health | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01704599 Background | Jan 2009 → Jun 2013 | psoriasis | Wayne State University | Terminated | No outcome recorded |
| Phase 233 trials | ||||||
| Phase 2 | NCT07622771 Background | Jun 2026 → Jun 2028 expected | rectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07423533 Comparator | Apr 2026 → Sep 2027 expected | rheumatoid arthritis | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07151937 Comparator | Nov 2025 → May 2027 expected | hidradenitis suppurativa | Almirall, S.A. | Recruiting | No outcome recorded |
| Phase 2 | NCT06037811 Comparator | Apr 2024 → Dec 2027 expected | arthritic joint disease | Tom Appleton | Recruiting | No outcome recorded |
| Phase 2 | NCT06242652 Comparator | Mar 2024 → Feb 2025 | ankylosing spondylitis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT06062875 Comparator | Jan 2024 → Apr 2028 expected | benign prostatic hyperplasia | Endeavor Health | Recruiting | No outcome recorded |
| Phase 2 | NCT05640245 Comparator | Dec 2022 → Sep 2023 | psoriatic arthritis | MoonLake Immunotherapeutics AG | Completed | No outcome recorded |
| Phase 2 | NCT05322473 Comparator | Apr 2022 → May 2023 | hidradenitis suppurativa | MoonLake Immunotherapeutics AG | Completed | No outcome recorded |
| Phase 2 | NCT04988308 Comparator | Oct 2021 → Oct 2022 | hidradenitis suppurativa | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04655807 Background | Mar 2021 → May 2023 | Crohn disease | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT05372939 Background | Feb 2021 → Jun 2022 | ulcerative colitis | Applied Molecular Transport | Completed | No outcome recorded |
| Phase 2 | NCT03248531 Comparator | Sep 2017 → Nov 2018 | hidradenitis suppurativa | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 2 | NCT02929251 Comparator | Jun 2017 → Oct 2021 | uveitis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT02862574 Background | Dec 2016 → Jun 2017 | rheumatoid arthritis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT02833350 Comparator | Sep 2016 → Jul 2018 | rheumatoid arthritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02706704 Comparator | Feb 2016 → Dec 2025 overdue | uveitis | American University of Beirut Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT02349451 Comparator | Apr 2015 → Jul 2016 | psoriatic arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02097264 Comparator | Sep 2014 → Sep 2015 | rheumatoid arthritis | Novo Nordisk A/S | Withdrawn | No outcome recorded |
| Phase 2 | NCT02141997 Comparator | Jul 2014 → Sep 2015 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01716039 Comparator | Jun 2013 → Jul 2016 | ulcerative colitis | Alimentiv Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01712178 Comparator | Jun 2012 → May 2013 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01483599 Comparator | Nov 2011 → Nov 2012 | psoriasis | Janssen, LP | Completed | No outcome recorded |
| Phase 2 | NCT02092961 Comparator | Feb 2011 → Jul 2013 | rheumatoid arthritis | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT01264770 Comparator | Jan 2011 → Oct 2012 | rheumatoid arthritis | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT01225393 Comparator | Nov 2010 → Jul 2012 | rheumatoid arthritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00595413 Comparator | Sep 2007 → Oct 2009 | rheumatoid arthritis | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT00550446 Comparator | Sep 2007 → Jan 2009 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00298272 Background | May 2006 → Apr 2009 | rheumatoid arthritis | Biogen | Terminated | No outcome recorded |
| Phase 2 | NCT00645892 Comparator | Nov 2003 → Sep 2004 | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00645905 Comparator | Jun 2003 → Mar 2005 | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00646191 Comparator | Mar 2003 → Jun 2004 | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00646386 Comparator | Mar 2003 → Apr 2004 | arthritic joint disease, psoriasis | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00645814 Comparator | Mar → Sep 2003 | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT05871086 Background | May → Dec 2023 | juvenile idiopathic arthritis | Nourhan Elsherif | Unknown | No outcome recorded |
| Phase 2/3 | NCT05299242 Comparator | Jul 2022 → May 2023 | frozen shoulder | University of Oxford | Completed | No outcome recorded |
| Phase 2/3 | NCT03759288 Comparator | Dec 2018 → Oct 2023 | Crohn disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 2/3 | NCT03217734 Comparator | Apr 2017 → Dec 2018 | psoriasis | Jeffrey J Crowley MD | Completed | No outcome recorded |
| Phase 369 trials | ||||||
| Phase 3 | NCT06640517 Comparator | Aug 2024 → Jun 2026 overdue | psoriasis | Biocad | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06333210 Comparator | Dec 2023 → Dec 2024 overdue | spondyloarthropathy | Biocad | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06005532 Comparator | Oct 2023 → Mar 2025 | psoriasis | Mabscale, LLC | Unknown | No outcome recorded |
| Phase 3 | NCT04643483 Comparator | Jun 2021 → Sep 2023 | Crohn disease | UCB Biopharma SRL | Withdrawn | No outcome recorded |
| Phase 3 | NCT04527380 Comparator | Apr 2021 → Feb 2024 overdue | enthesitis-related juvenile idiopathic arthritis, psoriasis-related juvenile idiopathic arthritis | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04115748 Comparator | Dec 2019 → Jan 2021 | psoriatic arthritis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT04088409 Comparator | Oct 2019 → Jul 2023 overdue | uveitis | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04404517 Comparator | Oct 2019 → Sep 2021 | inflammatory bowel disease | Hospital Universitario La Paz | Unknown | No outcome recorded |
| Phase 3 | NCT03828019 Comparator | Sep 2019 → Apr 2024 | uveitis | JHSPH Center for Clinical Trials | Completed | No outcome recorded |
| Phase 3 | NCT03927352 Comparator | Sep 2019 → Dec 2021 | psoriasis | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03895203 Comparator | Apr 2019 → Aug 2021 | psoriatic arthritis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03789292 Comparator | Nov 2018 → Oct 2019 | rheumatoid arthritis | Celltrion | Completed | No outcome recorded |
| Phase 3 | NCT03464136 Comparator | Mar 2018 → Dec 2020 | Crohn disease | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03412747 Comparator | Jan 2018 → Feb 2019 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03259074 Comparator | Nov 2017 → Nov 2021 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03316781 Comparator | Oct 2017 → Jul 2018 | psoriasis | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 3 | NCT03210259 Comparator | Jul 2017 → Apr 2019 | psoriasis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02745080 Comparator | Apr 2017 → Dec 2019 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04135508 Comparator | Dec 2016 → Mar 2018 | ankylosing spondylitis | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 3 | NCT02762955 Comparator | Dec 2016 → Dec 2017 | psoriasis | Biocad | Completed | No outcome recorded |
| Phase 3 | NCT02871635 Comparator | Sep 2016 → Apr 2019 | Crohn disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02893254 Comparator | Sep 2016 → Jan 2018 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02889796 Comparator | Aug 2016 → Jul 2018 | rheumatoid arthritis | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02850965 Comparator | Aug 2016 → Jan 2018 | psoriasis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02760407 Comparator | Jun 2016 → Aug 2019 | rheumatoid arthritis | R-Pharm International, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02696785 Comparator | May 2016 → Dec 2017 | spondyloarthropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02746380 Comparator | Apr 2016 → Jul 2017 | rheumatoid arthritis | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02744755 Comparator | Mar 2016 → Jan 2017 | rheumatoid arthritis | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT02694523 Comparator | Mar 2016 → Aug 2017 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02489227 Comparator | Aug 2015 → May 2016 | psoriasis | Coherus Oncology, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02497469 Comparator | Jun 2015 → Sep 2018 | ulcerative colitis | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT02480153 Comparator | Jun 2015 → Aug 2016 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02405780 Comparator | Jun 2015 → Jan 2018 | rheumatoid arthritis | Fujifilm Kyowa Kirin Biologics Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02714322 Comparator | Jun 2015 → May 2016 | psoriasis, psoriatic arthritis | Mylan Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02332590 Comparator | Jan 2015 → Jan 2016 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02137226 Comparator | Jan 2015 → Mar 2016 | rheumatoid arthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02260791 Comparator | Dec 2014 → Jul 2016 | rheumatoid arthritis | Fujifilm Kyowa Kirin Biologics Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02207231 Comparator | Nov 2014 → Sep 2015 | psoriasis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02171429 Comparator | Nov 2014 → Mar 2020 | ulcerative colitis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02163759 Comparator | Nov 2014 → Feb 2020 | ulcerative colitis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02207244 Comparator | Nov 2014 → Oct 2015 | psoriasis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02332356 Comparator | Sep 2014 → Mar 2024 | Crohn disease | Tokyo Medical and Dental University | Unknown | No outcome recorded |
| Phase 3 | NCT01870284 Comparator | Jul 2014 → Apr 2016 | ankylosing spondylitis | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 3 | NCT01877668 Comparator | Jan 2014 → Dec 2015 | psoriatic arthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02016482 Comparator | Jan 2014 → Oct 2015 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02016105 Comparator | Dec 2013 → Jul 2015 | psoriasis | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT01674413 Comparator | Oct 2013 → Mar 2016 | Crohn disease | Peter Higgins | Withdrawn | No outcome recorded |
| Phase 3 | NCT01970475 Comparator | Oct 2013 → Nov 2014 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT06441526 Comparator | Sep 2013 → Dec 2019 | Crohn disease, anal fistula | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 3 | NCT01764997 Background | Apr 2013 → Jan 2015 | rheumatoid arthritis | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT01695239 Comparator | Dec 2012 → Dec 2014 | psoriatic arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01562951 Comparator | Oct 2012 → Mar 2014 | Crohn disease, mucositis | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | Terminated | No outcome recorded |
| Phase 3 | NCT01710358 Comparator | Oct 2012 → Mar 2015 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01670240 Comparator | Aug 2012 → Sep 2015 | pouchitis, ulcerative colitis | Odense University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01564823 Comparator | Jun 2012 → Jan 2015 | Crohn disease | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | Completed | No outcome recorded |
| Phase 3 | NCT01724268 Comparator | May 2012 → May 2014 | rheumatoid arthritis | Hamad Medical Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT01185301 Comparator | Oct 2010 → Sep 2012 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00929864 Comparator | Oct 2009 → Oct 2011 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00853385 Comparator | May 2009 → Mar 2011 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00736983 Comparator | Sep 2008 → Sep 2011 | perianal Crohn disease | Foundation for Liver Research | Completed | No outcome recorded |
| Phase 3 | NCT03414502 Comparator | Dec 2007 → Mar 2028 expected | rheumatoid arthritis | University of Nebraska | Recruiting | No outcome recorded |
| Phase 3 | NCT00647270 Comparator | Dec 2007 → Apr 2009 | rheumatoid arthritis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00574249 Comparator | Nov 2007 → Oct 2008 | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00409682 Comparator | Apr 2007 → May 2010 | Crohn disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT01510548 Comparator | Mar 2007 → Jul 2014 | lumbar disk disease | Kuopio University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00305539 Comparator | May 2006 → May 2011 | temporal arteritis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00235820 Comparator | Jul 2005 → May 2006 | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00124982 Background | Apr 2005 → Aug 2009 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00646178 Comparator | Jun 2003 → Mar 2004 | psoriatic arthritis | Abbott | Completed | No outcome recorded |
| Phase 451 trials | ||||||
| Phase 4 | NCT07486843 Comparator | Mar 2026 → Dec 2027 expected | psoriatic arthritis | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 4 | NCT07013838 Comparator | Jun 2025 → Dec 2027 expected | Takayasu arteritis | Chinese SLE Treatment And Research Group | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06527534 Comparator | Jul 2024 → Jul 2025 overdue | rheumatoid arthritis | University of Verona | Recruiting | No outcome recorded |
| Phase 4 | NCT05928039 Comparator | Oct 2023 → Jul 2027 expected | Crohn disease | University of Calgary | Recruiting | No outcome recorded |
| Phase 4 | NCT05502731 Comparator | Oct 2022 → Mar 2025 | rheumatoid arthritis | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05313620 Comparator | Apr 2022 → Dec 2025 overdue | ulcerative colitis, venous thromboembolism | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Recruiting | No outcome recorded |
| Phase 4 | NCT05153200 Comparator | Jan 2022 → Jun 2023 | rheumatoid arthritis | Ottawa Hospital Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT05105347 Background | Nov 2021 → Dec 2026 expected | uveitis | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04985435 Comparator | May 2021 → Sep 2025 overdue | rheumatoid arthritis | R.Bos | Recruiting | No outcome recorded |
| Phase 4 | NCT04255134 Comparator | Sep 2020 → Oct 2022 | rheumatoid arthritis | St George's, University of London | Completed | No outcome recorded |
| Phase 4 | NCT05683054 Comparator | Aug 2020 → Mar 2022 | psoriasis | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT03816397 Comparator | Mar 2020 → Jan 2025 | juvenile idiopathic arthritis, uveitis | Nisha Acharya | Completed | No outcome recorded |
| Phase 4 | NCT04086745 Comparator | Feb 2020 → May 2025 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT04183608 Comparator | Jan 2020 → Apr 2025 overdue | ulcerative colitis | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Recruiting | No outcome recorded |
| Phase 4 | NCT03917303 Comparator | Dec 2019 → May 2024 overdue | Crohn disease | Maastricht University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT03885713 Comparator | Sep 2019 → Dec 2024 | Crohn disease, ulcerative colitis | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Completed | No outcome recorded |
| Phase 4 | NCT03619876 Comparator | Jul 2019 → Sep 2021 | myocarditis, rheumatoid arthritis | Columbia University | Terminated | No outcome recorded |
| Phase 4 | NCT03915964 Comparator | Apr 2019 → May 2025 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT03737708 Background | Feb 2019 → Jun 2020 | rheumatoid arthritis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT03445845 Comparator | Dec 2018 → Sep 2024 | spondyloarthropathy | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 4 | NCT03580876 Background | Jul 2018 → Jun 2019 | — | Védrines, Philippe, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT03100253 Comparator | Mar 2018 → Dec 2021 | rheumatoid arthritis | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded |
| Phase 4 | NCT03059849 Comparator | Feb 2018 → Feb 2019 | Crohn disease, ulcerative colitis | McMaster University | Withdrawn | No outcome recorded |
| Phase 4 | NCT03151551 Comparator | Aug 2017 → Nov 2018 | psoriatic arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT02994836 Comparator | Apr 2017 → Dec 2021 | Crohn disease, ulcerative colitis | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Completed | No outcome recorded |
| Phase 4 | NCT02808975 Comparator | Jul 2016 → May 2019 | hidradenitis suppurativa | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT02374021 Comparator | Jul 2016 → May 2021 | rheumatoid arthritis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02557100 Comparator | Nov 2015 → Mar 2019 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT02451748 Background | Aug 2015 → Sep 2017 | rheumatoid arthritis | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 4 | NCT02242474 Comparator | Jul 2015 → Oct 2019 | rheumatoid arthritis | CHU de Quebec-Universite Laval | Unknown | No outcome recorded |
| Phase 4 | NCT02353780 Comparator | Mar 2015 → Dec 2017 | rheumatoid arthritis | Dr. Larry W. Moreland | Terminated | No outcome recorded |
| Phase 4 | NCT02187055 Comparator | Aug 2014 → Dec 2016 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT02092467 Comparator | Mar 2014 → Jul 2020 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT02056184 Background | Dec 2013 → Dec 2017 | rheumatoid arthritis | University of Leeds | Completed | No outcome recorded |
| Phase 4 | NCT02236481 Comparator | Jul 2013 → Dec 2017 | rheumatoid arthritis, type 2 diabetes mellitus | Prof. Roberto Giacomelli | Terminated | No outcome recorded |
| Phase 4 | NCT01793519 Comparator | Jan 2013 → Jun 2024 | rheumatoid arthritis | Georgetown University | Unknown | No outcome recorded |
| Phase 4 | NCT01553058 Comparator | Jul 2012 → Aug 2016 | cardiovascular disorder, psoriasis | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT01500278 Comparator | Dec 2011 → Nov 2015 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 4 | NCT01400516 Background | Aug 2011 → Jul 2015 | rheumatoid arthritis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01283971 Comparator | May 2011 → Aug 2012 | rheumatoid arthritis | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 4 | NCT01237262 Comparator | Nov 2010 | psoriasis | University of Padova | Unknown | No outcome recorded |
| Phase 4 | NCT01174186 Comparator | Oct 2010 → Jun 2013 | enterocolitis, spondyloarthropathy | Regionshospitalet Silkeborg | Completed | No outcome recorded |
| Phase 4 | NCT01119859 Comparator | May 2010 → Jan 2012 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT01021735 Comparator | Apr 2010 → Dec 2014 | rheumatoid arthritis | University of Glasgow | Completed | No outcome recorded |
| Phase 4 | NCT01000441 Comparator | Dec 2009 → Aug 2013 | rheumatoid arthritis | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| Phase 4 | NCT01029847 Comparator | Dec 2009 → Dec 2013 | spondyloarthropathy | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT00932113 Comparator | Jun 2009 → Dec 2011 | psoriasis | Tufts Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00808509 Comparator | Jan 2009 → Sep 2012 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT00735787 Comparator | Aug 2008 → Sep 2009 | psoriasis | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT00477893 Comparator | Feb 2006 → Jan 2009 | spondyloarthropathy | Glostrup University Hospital, Copenhagen | Unknown | No outcome recorded |
| Phase 4 | NCT00233558 Background | Jun 2005 → ? | rheumatoid arthritis | Abbott | Terminated | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT07529236 Background | Apr 2026 → Oct 2027 expected | inflammatory bowel disease | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| — | NCT07128472 Comparator | Aug 2025 → Jan 2026 overdue | psoriasis | South Valley University | Recruiting | No outcome recorded |
| — | NCT06896305 Background | May 2025 → Apr 2027 expected | Crohn disease, ulcerative colitis | IRCCS Ospedale San Raffaele | Recruiting | No outcome recorded |
| — | NCT06729463 Comparator | Dec 2024 → Mar 2025 | psoriasis, psoriatic arthritis | South Valley University | Completed | No outcome recorded |
| — | NCT05889338 Comparator | Jun 2023 → Jan 2024 | psoriasis | Sohag University | Unknown | No outcome recorded |
| — | NCT05291039 Comparator | Jan 2022 → Mar 2023 | inflammatory bowel disease | Rehab Werida | Completed | No outcome recorded |
| — | NCT04882683 Background | Jun 2021 → Jun 2022 | ulcerative colitis | Shandong Qilu Stem Cells Engineering Co., Ltd. | Unknown | No outcome recorded |
| — | NCT03561649 Background | Jun 2018 → Dec 2019 | ankylosing spondylitis | University Hospital, Grenoble | Completed | No outcome recorded |
| — | NCT03261102 Comparator | Jan 2017 → Jan 2025 overdue | Crohn disease | waqqas.afif | Active not recruiting | No outcome recorded |
| — | NCT02878083 Background | Jan 2017 → Jan 2020 | ulcerative colitis | Nantes University Hospital | Terminated | No outcome recorded |
| — | NCT02539849 Background | Dec 2014 → Dec 2017 | Crohn disease | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| — | NCT01657513 Background | Jun 2012 → Jul 2013 | psoriasis | University Hospital, Gentofte, Copenhagen | Unknown | No outcome recorded |
| — | NCT01610947 Comparator | May 2012 → Oct 2018 | spondyloarthropathy | University Hospital, Montpellier | Completed | No outcome recorded |
| — | NCT01197144 Comparator | Oct 2010 → Nov 2016 | rheumatoid arthritis | Karolinska Institutet | Completed | No outcome recorded |
Press releases naming this drug 98 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-20 | AbbVie | RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor abbvie.com ↗ |
| 2025-05-27 | Organon and Co | US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection organon.com ↗ |
| 2024-05-20 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. tevapharm.com ↗ |
| 2024-04-30 | Teva Branded Pharmaceutical Products R&D, Inc. | U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) tevapharm.com ↗ |
| 2024-04-15 | Organon and Co | Organon’s HADLIMA™ (adalimumab-bwwd) and NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) Added to Mark Cuban’s Cost Plus Drugs organon.com ↗ |
| 2024-02-23 | Teva Branded Pharmaceutical Products R&D, Inc. | Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® tevapharm.com ↗ |
| 2024-02-20 | Organon and Co | Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary organon.com ↗ |
| 2023-11-07 | Organon and Co | Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira® organon.com ↗ |
| 2023-08-01 | Organon and Co | Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar organon.com ↗ |
| 2023-07-01 | Organon and Co | Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator organon.com ↗ |
| 2023-07-01 | Novartis Pharmaceuticals | Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space novartis.com ↗ |
| 2023-04-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Complete Response Letter Received for AVT02 Biologics License Application tevapharm.com ↗ |
| 2023-04-03 | Novartis Pharmaceuticals | Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation novartis.com ↗ |
| 2023-03-21 | Novartis Pharmaceuticals | Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation novartis.com ↗ |
| 2023-01-31 | Amgen | AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES amgen.com ↗ |
| 2023-01-30 | Novartis Pharmaceuticals | Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar novartis.com ↗ |
| 2022-08-17 | Organon and Co | Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd) organon.com ↗ |
| 2022-07-21 | Novartis Pharmaceuticals | Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) novartis.com ↗ |
| 2022-06-17 | Novartis Pharmaceuticals | Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA novartis.com ↗ |
| 2022-03-08 | AbbVie | AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech abbvie.com ↗ |
| 2022-01-05 | Organon and Co | FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate organon.com ↗ |
| 2021-02-24 | AbbVie | HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis abbvie.com ↗ |
| 2019-11-18 | Pfizer | FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions pfizer.com ↗ |
| 2019-11-01 | Novartis Pharmaceuticals | Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis novartis.com ↗ |
| 2019-09-25 | Takeda | First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab takeda.com ↗ |
| 2019-06-14 | Novartis Pharmaceuticals | New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy novartis.com ↗ |
| 2019-05-19 | Takeda | New Exploratory Data from VARSITY, the First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week ® takeda.com ↗ |
| 2019-05-14 | AbbVie | AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim abbvie.com ↗ |
| 2019-03-09 | Takeda | Vedolizumab (Entyvio ® ) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira ® ) in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis takeda.com ↗ |
| 2018-11-30 | AbbVie | AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer abbvie.com ↗ |
| 2018-11-06 | AbbVie | AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta abbvie.com ↗ |
| 2018-10-31 | Novartis Pharmaceuticals | Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz) novartis.com ↗ |
| 2018-10-18 | AbbVie | AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi abbvie.com ↗ |
| 2018-10-15 | Amgen | Amgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe amgen.com ↗ |
| 2018-10-11 | Novartis Pharmaceuticals | Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access novartis.com ↗ |
| 2018-10-11 | AbbVie | AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz abbvie.com ↗ |
| 2018-10-08 | AbbVie | AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting abbvie.com ↗ |
| 2018-07-27 | Novartis Pharmaceuticals | Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab) novartis.com ↗ |
| 2018-07-17 | AbbVie | AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan abbvie.com ↗ |
| 2018-06-01 | Novartis Pharmaceuticals | Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab novartis.com ↗ |
| 2018-04-09 | AbbVie | Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis abbvie.com ↗ |
| 2018-04-05 | AbbVie | AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis abbvie.com ↗ |
| 2018-01-16 | Novartis Pharmaceuticals | Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA novartis.com ↗ |
| 2018-01-16 | AbbVie | HUMIRA® (adalimumab) Formulation Update abbvie.com ↗ |
| 2018-01-09 | Novartis Pharmaceuticals | Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab** novartis.com ↗ |
| 2017-11-05 | Incyte Corporation | ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo incyte.com ↗ |
| 2017-09-28 | Amgen | Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA™ amgen.com ↗ |
| 2017-09-28 | AbbVie | AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen abbvie.com ↗ |
| 2017-09-14 | Novartis Pharmaceuticals | Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study novartis.com ↗ |
| 2017-07-21 | AbbVie | AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis abbvie.com ↗ |
| 2017-05-31 | Novartis Pharmaceuticals | Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency novartis.com ↗ |
| 2017-03-30 | AbbVie | U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing Information abbvie.com ↗ |
| 2017-03-23 | Amgen | European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases amgen.com ↗ |
| 2017-03-06 | Novartis Pharmaceuticals | New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine novartis.com ↗ |
| 2017-02-16 | Pfizer | Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab) pfizer.com ↗ |
| 2017-02-15 | Incyte Corporation | Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo incyte.com ↗ |
| 2017-01-27 | Amgen | Amgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases amgen.com ↗ |
| 2017-01-05 | Pfizer | Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab) pfizer.com ↗ |
| 2016-11-14 | AbbVie | AbbVie's HUMIRA® (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease abbvie.com ↗ |
| 2016-11-14 | Incyte Corporation | Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes incyte.com ↗ |
| 2016-09-23 | Amgen | FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases amgen.com ↗ |
| 2016-07-14 | AbbVie | AbbVie’s Open Public Hearing Comments at FDA Arthritis Advisory Committee Meeting – July 12, 2016, for ABP 501 abbvie.com ↗ |
| 2016-07-12 | Amgen | Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab amgen.com ↗ |
| 2016-07-07 | AbbVie | AbbVie Presents Initial Data from Pivotal Phase-3 Trial Evaluating the Efficacy and Safety of HUMIRA® (adalimumab) for Moderate to Severe Fingernail Psoriasis in Adult Patients at Psoriasis 2016 Congress abbvie.com ↗ |
| 2016-06-30 | AbbVie | AbbVie's HUMIRA® (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis abbvie.com ↗ |
| 2016-06-13 | Amgen | Amgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab amgen.com ↗ |
| 2016-05-27 | AbbVie | AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1] abbvie.com ↗ |
| 2016-05-19 | AbbVie | AbbVie's Leadership in Gastroenterology Showcased at Digestive Disease Week® with New HUMIRA® (adalimumab) Long-Term, Real-World Research and Promising Anti-IL-23 Antibody Late-Breaking Data abbvie.com ↗ |
| 2016-04-04 | AbbVie | AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease abbvie.com ↗ |
| 2016-03-02 | AbbVie | AbbVie Announces New Dermatology Research from More Than 35 Presentations on HUMIRA® (Adalimumab), Long-Term and Real-World Data at the American Academy of Dermatology 2016 Annual Meeting abbvie.com ↗ |
| 2016-01-25 | Amgen | FDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501 amgen.com ↗ |
| 2015-12-03 | Amgen | Amgen's First Biosimilar Marketing Authorization Application Submitted To European Medicines Agency For ABP 501 amgen.com ↗ |
| 2015-11-25 | Amgen | Amgen's First Biosimilar Biologics License Application For ABP 501 Submitted To U.S. Food And Drug Administration amgen.com ↗ |
| 2015-11-09 | Amgen | Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab amgen.com ↗ |
| 2015-11-07 | Incyte Corporation | Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis incyte.com ↗ |
| 2015-11-03 | AbbVie | AbbVie's Leadership and Innovation in Immunology Showcased at the American College of Rheumatology Annual Meeting with More Than 40 Abstracts on HUMIRA® (adalimumab) and Investigational Medicines Across Multiple Inflammatory Diseases abbvie.com ↗ |
| 2015-10-14 | Incyte Corporation | Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study incyte.com ↗ |
| 2015-09-10 | AbbVie | AbbVie's HUMIRA® (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa abbvie.com ↗ |
| 2015-07-30 | AbbVie | HUMIRA® (Adalimumab) Approved by European Commission for Moderate to Severe Hidradenitis Suppurativa (HS) abbvie.com ↗ |
| 2015-06-26 | AbbVie | AbbVie's HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Adult Patients with Active Moderate to Severe Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease abbvie.com ↗ |
| 2015-06-09 | AbbVie | AbbVie Presents Phase 3 Data Demonstrating Efficacy and Safety of HUMIRA® (adalimumab) in Children and Adolescents with Severe Chronic Plaque Psoriasis at the 23rd World Congress of Dermatology abbvie.com ↗ |
| 2015-05-15 | AbbVie | AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa (HS) abbvie.com ↗ |
| 2015-05-05 | AbbVie | AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy and Safety of HUMIRA® (adalimumab) in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis abbvie.com ↗ |
| 2015-04-01 | AbbVie | AbbVie's HUMIRA® (Adalimumab) Approved by European Commission to Treat Children and Adolescents with Severe Chronic Plaque Psoriasis abbvie.com ↗ |
| 2015-03-17 | AbbVie | AbbVie's Dermatology Leadership Showcased with HUMIRA® (adalimumab) Data at American Academy of Dermatology 2015 Annual Meeting abbvie.com ↗ |
| 2015-02-27 | AbbVie | AbbVie's HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Children and Adolescents With Severe Chronic Plaque Psoriasis abbvie.com ↗ |
| 2015-02-03 | Amgen | Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis amgen.com ↗ |
| 2014-11-13 | AbbVie | AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab) abbvie.com ↗ |
| 2014-10-13 | AbbVie | AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress abbvie.com ↗ |
| 2014-10-06 | AbbVie | AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for Extension of Polyarticular Juvenile Idiopathic Arthritis Indication to Patients Ages 2 and Older abbvie.com ↗ |
| 2014-09-25 | AbbVie | AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease abbvie.com ↗ |
| 2014-09-11 | AbbVie | AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease abbvie.com ↗ |
| 2014-05-20 | AbbVie | AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis abbvie.com ↗ |
| 2014-03-20 | AbbVie | AbbVie Initiates New Clinical Trial to Evaluate HUMIRA® (adalimumab) for the Treatment of Fingernail Psoriasis in Patients with Moderate to Severe Chronic Plaque Psoriasis abbvie.com ↗ |
| 2013-10-03 | AbbVie | AbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease abbvie.com ↗ |
| 2013-06-13 | AbbVie | AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA® (adalimumab) for Rheumatoid Arthritis abbvie.com ↗ |
| 2013-02-15 | AbbVie | AbbVie Announces First Long-term, Patient-Reported Health Outcomes Data for Use of HUMIRA® (Adalimumab) in Patients with Pediatric Crohn's Disease abbvie.com ↗ |
| 2012-06-06 | Bristol-Myers Squibb | ORENCIA® (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents bms.com ↗ |
Evidence & citations 47 cited values
Every value below carries the sentence it was read from. 516 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adalimumab | “A total of 216 patients with inflammatory bowel disease from the Inflammatory Unit of the Virgin Macarena University Hospital will be randomized 1:1 to receive the study drug,...” NCT04131322 ↗459“The cohort A (borderline resectable) and cohort B (locally advanced) both received treatment with gemcitabine, albumin paclitaxel (administered on days 1, 8, and 15, with 4...” NCT07208539 ↗ “An international multicentre randomized trial of a humanized monoclonal antibody, adalimumab, in JIA has demonstrated its efficacy on joint lesions and its good safety as...” NCT01385826 ↗ “To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing...” NCT05115903 ↗ “Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC OR Loss of response under Adalimumab: 40mg EW SC Randomization to: Infliximab: 5mg/kg IV at...” NCT03580876 ↗ “RA treated with subcutaneous TNF-blockers (etanercept or adalimumab) at stable and standard dosage for 1 year or more, as monotherapy or associated with stable conventional DMARD;” NCT00780793 ↗ “TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi)” NCT04378621 ↗ “Adalimumab (Humira; Abbott Laboratories, Abbot Park, IL) is a fully human, monoclonal antibody directed against TNF-α and is approved by the US FDA to treat rheumatoid arthritis.” NCT00731757 ↗ “Adalimumab-adbm (Cyltezo®) is approved by the US Food and Drug Administration as an interchangeable biosimilar to the adalimumab reference product (RP; Humira®).” PMID 40498294 ↗ Jun 2025 “infliximab, and adalimumab are the main TNF inhibitors available for children10 and are used in the treatment of refractory or chronic childhood uveitis 11,12 .” NCT05540743 ↗ “These medicines were reference adalimumab (brand name Humira®) and biosimilar GP2017 (also known as Sandoz-adalimumab and sold under the brand name Hyrimoz®).” PMID 41709696 ↗ Feb 2026 “The VOLTAIRE-CD study aimed to show whether BI 695501 is just as effective and safe as the original drug, adalimumab (Humira®) in treating Crohn's disease.” PMID 36511191 ↗ Dec 2022 “An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.” NCT02862574 ↗ “Evaluation of the Safety and Effectiveness of Switching From Originator (Humira®) to Biosimilar (Imraldi®) Adalimumab in Flanders (SafE-OrBi)” NCT04045782 ↗ “Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months” NCT00124982 ↗ “Participants were randomised to anakinra or to a TNFi (i.e., adalimumab, certolizumab pegol, etanercept, infliximab, or golimumab)” PMID 31513665 ↗ Sep 2019 “Seton placement, followed by anti-TNF medication (infliximab or adalimumab) in combination with a immunomodulator after ± 2 weeks.” NCT06441526 ↗ “Humira (adalimumab) is a monoclonal antibody targeting TNF-α, widely used for treating moderate-to-severe psoriasis and PsA.” NCT07128472 ↗ “Anti-TNF drugs (infliximab and adalimumab) are used early in high-risk patients or when standard treatments have failed.” NCT07529236 ↗ “Adalimumab: 160 mg subcutaneous (SC) at day 0, 80 mg SC at week 2, 40 mg SC at week 4 and every two weeks thereafter.” NCT05169593 ↗ “Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.” NCT04028713 ↗ “Participants received a TNF inhibitor (adalimumab or etanercept) administered according to approved local labeling” NCT03915964 ↗ “albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adalimumab 1200mg are administered intravenously.” NCT07137858 ↗ “United States-licensed adalimumab (US-adalimumab) and European Union-approved adalimumab (EU-adalimumab)” PMID 33503313 ↗ Mar 2021 “Adalimumab-adbm is a monoclonal antibody developed as a biosimilar to adalimumab (Humira, AbbVie Inc.).” PMID 32363771 ↗ Jun 2020 “Three Formulations of Adalimumab (SB5, EU sourced Humira® and US sourced Humira®) in Healthy Subjects” NCT02144714 ↗ “Patients were randomized (1 : 1) to receive ABP 501 or adalimumab 40 mg every 2 weeks for 16 weeks.” PMID 28755394 ↗ Dec 2017 “adalimumab at 40 mg every 2 weeks or etanercept 50 mg per week according to treatments history” NCT04870203 ↗ “TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)” NCT01400516 ↗ “PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects” NCT02237729 ↗ “subcutaneous injection of adalimumab in combination with MTX (methotrexate)” NCT06528431 ↗ “adalimumab if initial failure to the receptor fusion protein, etanercept.” NCT03100253 ↗ “Adalimumab is a monoclonal antibody against tumor necrosis factor alpha” NCT02395055 ↗ “Adalimumab (Humira) is a fully human antibody directed against TNF-α.” NCT00730717 ↗ “Adalimumab 10 kg (22 lbs) to <15 kg (33 lbs) 10 mg every other week” NCT06654882 ↗ “Adalimumab subcutaneous injections 40 mg once every two weeks” NCT04985435 ↗ “adalimumab: 40mg every other week in subcutaneous injection” NCT03445845 ↗ “adalimumab (monoclonal antibody) 40 mg sc every 2 weeks” NCT05305066 ↗ “Etanrcept: 50 mg; Adalimumab: 40 mg; Infliximab: 3mg/kg” NCT01724268 ↗ “* Adalimumab - Weight based, 10-40 mg every other week” NCT05871086 ↗ “An active comparator, adalimumab, is also included.” NCT00853385 ↗ “Adalimumab, etanercept, certolizumab, or golimumab” NCT05379322 ↗ “Methotrexate or leflunomide + adalimumab or” NCT02714634 ↗ “after administration of adalimumab” NCT04439929 ↗ “HUMIRA® (Adalimumab) 40 mg/0.4 mL” NCT07147257 ↗ “Adalimumab(Humira) and NSAIDs” NCT02456363 ↗ “Adalimumab: 40 mg / 3 weeks” NCT01604629 ↗ “Humira SC (adalimumab)” NCT03789292 ↗ “Humira® (Adalimumab)” NCT02714322 ↗ “Adalimumab (Humira®)” NCT02779114 ↗ “Humira (adalimumab)” NCT05372939 ↗ “Humira (Adalimumab)” NCT05510063 ↗ “Humira (adalimumab)” NCT02167139 ↗ “Adalimumab (Humira)” NCT07149792 ↗ “Adalimumab” NCT05080218 ↗ “Adalimumab” NCT02242474 ↗ |
| Known as | ABP 501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05909852 ↗ |
| Known as | ABP 501-HCF | “ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 mL (ABP 501-LCF)” NCT05909852 ↗ |
| Known as | ABP 501-LCF | “ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 mL (ABP 501-LCF)” NCT05909852 ↗ |
| Known as | ADA | “Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, is effective in the treatment of many rheumatic diseases. ADA as the initial treatment in adult...” NCT04588818 ↗23“the influence of symptom duration on treatment response and on the correlation between improvements in patient reported outcomes (PRO) and objective inflammation in patients...” PMID 24476416 ↗ Jan 2014 “The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in...” PMID 26819752 ↗ Jan 2016 “The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in...” NCT02196701 ↗ “treatment with tofacitinib monotherapy versus tofacitinib or adalimumab (ADA) in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) with inadequate...” PMID 31673419 ↗ Oct 2019 “In the SPIRIT-H2H (ClinicalTrials.gov: NCT03151551) trial in biologic-naïve patients with active psoriatic arthritis (PsA), ixekizumab (IXE) was superior to adalimumab (ADA) at week 24” PMID 33200394 ↗ Nov 2020 “Adalimumab (ADA) is a subcutaneously (SC) self-administered fully human Ig G1 monoclonal antibody directed against tumor necrosis factor alpha (TNFα) which will be used intravitreally.” NCT00855608 ↗ “Adalimumab (ADA) was evaluated for its efficacy in patients with moderate to severely active psoriatic arthritis (PsA) and for the presence of correlations in disease change variables.” PMID 25834212 ↗ Apr 2015 “PURPOSES: This study investigated the feasibility of adalimumab (ADA) dose reduction and withdrawal strategy in children with stable pediatric non-infectious uveitis (PNIU).” PMID 38652891 ↗ Apr 2024 “comparing the efficacy, safety and cost-effectiveness of methotrexate (MTX), adalimumab (ADA), or their combination in non-infectious non-anterior uveitis.” NCT04798755 ↗ “Adalimumab (ADA), an anti-TNFα monoclonal antibody, has marketing authorization and is widely used in the treatment of UCNI as a relay to corticosteroids.” NCT06390436 ↗ “MUSICA evaluated methotrexate (MTX) 20 mg/week versus 7.5 mg/week in combination with adalimumab (ADA) in RA patients with an inadequate response to MTX.” PMID 30173153 ↗ Sep 2018 “their response to adalimumab (ADA) treatment and agreement with clinical measures of disease activity in patients with axial spondyloarthritis (axSpA).” PMID 30936290 ↗ Apr 2019 “OBJECTIVE: To evaluate the long-term effectiveness and safety of 10 years of adalimumab (ADA) treatment in DMARD-refractory RA patients and to analyse” PMID 26199453 ↗ Jul 2015 “Randomised trials have described the benefits of adalimumab [ADA] for ulcerative colitis [UC]” PMID 28981846 ↗ Oct 2017 “adalimumab (ADA), a fully human monoclonal antibody that selectively inhibits TNF-α” NCT07348588 ↗ “either Adalimumab (ADA) 40 mg/0.8 mL,every other week (EOW) or matching placebo” NCT02471118 ↗ “Eligible patients are those who are planned to start Adalimumab (ADA).” NCT02256462 ↗ “the dose of adalimumab (ADA) is limited to 40 mg every other week” NCT01270035 ↗ “reference arm (adalimumab (ADA) 40 mg every 2 weeks)” PMID 37696588 ↗ Sep 2023 “after receiving adalimumab (ADA) in a Phase 3 study” PMID 39702318 ↗ Dec 2024 “Biological: adalimumab (ADA)” NCT02814175 ↗ “Adalimumab (ADA)” NCT03828019 ↗ “adalimumab (ADA)” PMID 33492239 ↗ Jan 2021 |
| Known as | Adalimumab+NALIRIFOX→Short course radiotherapy →Adalimumab+NALIRIFOX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07622771 ↗ |
| Known as | adalimumab, ABT-D2E7, Humira | “adalimumab, ABT-D2E7, Humira” NCT00690573 ↗ |
| Known as | adalimumab-680LT | “fluorescently labeled adalimumab (adalimumab-680LT)” NCT07258641 ↗ |
| Known as | adalimumab-atto | “Adalimumab-atto (AMJEVITA®, USA)/AMGEVITA®, EU; Amgen Inc.), also known as ABP 501, is an approved biosimilar to adalimumab (HUMIRA®, AbbVie Inc.).” PMID 41954860 ↗ Apr 2026 |
| Known as | Adalimumab-EU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02237729 ↗ |
| Known as | ADL | “We aimed to assess the effect of adalimumab (ADL) treatment on linear growth in children with CD in a post-hoc analysis of the Pediatric Crohn's Disease AdalImumab Level-based...” PMID 32324651 ↗ Aug 20201“adalimumab (ADL) biosimilar PF-06410293 (ADL-PF: adalimumab-afzb; Abrilada®/Amsparity®/Xilbrilada®)” PMID 35304684 ↗ Mar 2022 |
| Known as | ADL-EU | “reference ADL sourced from the European Union (ADL-EU)” PMID 34563243 ↗ Sep 2021 |
| Known as | ADM | “Here, we aimed to evaluate the feasibility and volunteers' perception of home microsampling for quantification of adalimumab (ADM) concentrations in psoriasis patients.” PMID 35683398 ↗ May 2022 |
| Known as | Advixa | “Incepta Pharmaceuticals Ltd. Bangladesh has introduced Bangladesh's first locally manufactured adalimumab biosimilar Advixa that is available at a fraction of Humira's cost.” NCT05172817 ↗ |
| Known as | AMGEVITA | “Adalimumab-atto (AMJEVITA®, USA)/AMGEVITA®, EU; Amgen Inc.), also known as ABP 501, is an approved biosimilar to adalimumab (HUMIRA®, AbbVie Inc.).” PMID 41954860 ↗ Apr 20262“Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio” NCT05781152 ↗ |
| Known as | AMJEVITA | “Adalimumab-atto (AMJEVITA®, USA)/AMGEVITA®, EU; Amgen Inc.), also known as ABP 501, is an approved biosimilar to adalimumab (HUMIRA®, AbbVie Inc.).” PMID 41954860 ↗ Apr 2026 |
| Known as | AVT02 | “who selfinject AVT02 (adalimumab) subcutaneously (SC).” NCT04224194 ↗ |
| Known as | BCD-057 | “Adalimumab (BCD-057) 100 mg/mL” NCT07181694 ↗ |
| Known as | CinnoRA | “This study aimed to compare efficacy and safety of test-adalimumab (CinnoRA®, CinnaGen, Iran) to the innovator product (Humira®, AbbVie, USA) in adult patients with active...” PMID 28728599 ↗ Jul 2017 |
| Known as | D2E7 | “A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Moderate to...” NCT00195689 ↗6“A Multi-Centre Randomized, Double-Blind Study Comparing Adalimumab (D2E7) Plus Methotrexate With Placebo Plus Methotrexate on Work Disability in Subjects With Early Rheumatoid Arthritis” NCT00234845 ↗ “A Multi-Center Continuation Study of the Human Anti-TNF Antibody D2E7 Administered as a Subcutaneous Injection in Patients With Rheumatoid Arthritis” NCT00195650 ↗ “the Fully Human Anti-TNF-α Monoclonal Antibody Adalimumab (D2E7) When Added to Inadequate Standard Anti-Rheumatic Therapy” NCT00448383 ↗ “Adalimumab (D2E7)” NCT00055523 ↗ “adalimumab (D2E7)” NCT00195819 ↗ “adalimumab (D2E7)” NCT00085644 ↗ |
| Known as | Drug: Adalimumab (Humira) | “Drug: Adalimumab (Humira)” NCT02456363 ↗ |
| Known as | EU-adalimumab | “European Union-approved adalimumab (EU-adalimumab)” PMID 33503313 ↗ Mar 2021 |
| Known as | EU-Humira | “Participants received EU-Humira subcutaneously in EU-Humira, EU-Humira/EU-Humira and EU-Humira/MSB11022 arm.” NCT02660580 ↗1“EU-Humira 100mg/mL (Adalimumab Originator)” NCT03849404 ↗ |
| Known as | FITC-Adalimumab | “The study product FITC-Adalimumab will be topically applied via a spray catheter to the intestinal mucosa of Crohn's disease patients during endomicroscopy of the gut.” NCT01275508 ↗ |
| Known as | GP-2017 | “Sandoz adalimumab SDZ-ADL (GP-2017) is an approved adalimumab biosimilar.” PMID 33119861 ↗ Dec 2020 |
| Known as | Hadlima | “Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio” NCT05781152 ↗ |
| Known as | Hulio | “Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio” NCT05781152 ↗ |
| Known as | Humira | “This study aimed to compare efficacy and safety of test-adalimumab (CinnoRA®, CinnaGen, Iran) to the innovator product (Humira®, AbbVie, USA) in adult patients with active...” PMID 28728599 ↗ Jul 201764“Adalimumab (Humira; Abbott Laboratories, Abbot Park, IL) is a fully human, monoclonal antibody directed against TNF-α and is approved by the US FDA to treat rheumatoid arthritis.” NCT00731757 ↗ “Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.” NCT00726804 ↗ “Adalimumab (Humira, AbbVie) is a highly effective treatment for a variety of auto-immune/auto-inflammatory diseases including juvenile idiopathic arthritis (JIA).” NCT03607903 ↗ “The purpose of this study is to assess the effect of adalimumab (Humira), when compared to NB-UVB (narrow-band ultraviolet B) phototherapy or placebo” NCT01553058 ↗ “Evaluation of the Safety and Effectiveness of Switching From Originator (Humira®) to Biosimilar (Imraldi®) Adalimumab in Flanders (SafE-OrBi)” NCT04045782 ↗ “The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.” NCT03927352 ↗ “Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)” NCT02097264 ↗ “One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)” NCT00550446 ↗ “a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source” NCT03254810 ↗ “40mg Humira® (Adalimumab - US licensed Humira) by subcutaneous injection every other week up to 24 weeks” NCT02744755 ↗ “Active Study Drug is Adalimumab (Humira) which is FDA approved to treat rheumatoid arthritis since 2003.” NCT01893996 ↗ “Adalimumab-adbm is a monoclonal antibody developed as a biosimilar to adalimumab (Humira, AbbVie Inc.).” PMID 32363771 ↗ Jun 2020 “Systemic adalimumab: Subcutaneous injection of 40 mg adalimumab (Humira) given every 2 weeks.” NCT02706704 ↗ “Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio” NCT05781152 ↗ “Efficacy of Adalimumab (Humira®) in Spondyloarthritis Related to Crohn's Disease” NCT00972218 ↗ “PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects” NCT02237729 ↗ “The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi.” NCT01548768 ↗ “the drug adalimumab (also called Humira) can decrease pain and stiffness” NCT02437253 ↗ “Adalimumab (Humira) is a fully human antibody directed against TNF-α.” NCT00730717 ↗ “Biological: Humira® (adalimumab) AC Pen [Reference Product]” NCT06291948 ↗ “Adalimumab (Humira) 40 mg subcutaneously every other week” NCT00696059 ↗ “Adalimumab (Humira®): TNF-α antibody BB-IND #11714:” NCT00193648 ↗ “anti-TNF (adalimumab, Humira®, Abbott) 40 mg s.c.” PMID 25371053 ↗ Nov 2014 “Adalimumab (Humira) Etanercept (Enbrel)” NCT04985435 ↗ “Biological: Humira (adalimumab-EU)” NCT01870986 ↗ “Adalimumab 100 MG/ML [Humira]” NCT03579823 ↗ “Adalimumab Injection [Humira]” NCT03153319 ↗ “Adalimumab (Humira) 100 mg/mL” NCT07181694 ↗ “Adalimumab (Humira®)” NCT02779114 ↗ “Adalimumab (Humira)” NCT01497717 ↗ “Adalimumab (Humira)” NCT07149792 ↗ “Adalimumab (Humira)” NCT06926478 ↗ “adalimumab (Humira)” NCT00478660 ↗ “Humira (adalimumab)” NCT00512863 ↗ “Humira, Adalimumab” NCT01088165 ↗ |
| Known as | humira (adalimumab) | “humira (adalimumab)” NCT00480272 ↗ |
| Known as | HumiraR | “The main objective of this studies therapeutic : to determine the effect of Adalimumab (HumiraR) on clinical inflammatory manifestations of patients with Netherton syndrome...” NCT02113904 ↗ |
| Known as | Hyrimoz | “These medicines were reference adalimumab (brand name Humira®) and biosimilar GP2017 (also known as Sandoz-adalimumab and sold under the brand name Hyrimoz®).” PMID 41709696 ↗ Feb 20261“Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio” NCT05781152 ↗ |
| Known as | Idacio | “Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio” NCT05781152 ↗1“Adalimumab(Idacio) 40 mg subcutaneously (sc) every other week” NCT05153200 ↗ |
| Known as | Imraldi | “Evaluation of the Safety and Effectiveness of Switching From Originator (Humira®) to Biosimilar (Imraldi®) Adalimumab in Flanders (SafE-OrBi)” NCT04045782 ↗ |
| Known as | LBAL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02206867 ↗ |
| Known as | ref-ADL | “Both studies evaluated and confirmed equivalent efficacy, similar safety, and immunogenicity of SDZ-ADL with reference adalimumab (ref-ADL).” PMID 33651341 ↗ Mar 2021 |
| Known as | Sandoz-adalimumab | “These medicines were reference adalimumab (brand name Humira®) and biosimilar GP2017 (also known as Sandoz-adalimumab and sold under the brand name Hyrimoz®).” PMID 41709696 ↗ Feb 2026 |
| Known as | SB5 | “Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis.” PMID 30561229 ↗ Jan 2019 |
| Known as | SDZ-ADL | “An adalimumab (tumor necrosis factor [TNF] inhibitor) biosimilar, GP2017 (SDZ-ADL; Sandoz), has been approved by the European Medicines Agency (July 2018) for use in all same...” PMID 31983056 ↗ Mar 20201“SDZ-ADL (GP2017; Sandoz GmbH, Austria) is an EMA-/FDA-approved adalimumab biosimilar.” PMID 33651341 ↗ Mar 2021 |
| Known as | symponi | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02353780 ↗ |
| Known as | Tabellvi | “Tabellvi® (Adalimumab) in Chinese Adult Subjects With Moderate to Severe Active Crohn's Disease” NCT07663526 ↗ |
| Known as | Tebiovio | “Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis” NCT07663331 ↗ |
| Known as | TyboWe | “TyboWe® Adalimumab Injection” NCT07663331 ↗1“TyboWe® Adalimumab Injection” NCT07663526 ↗ |
| Known as | US-adalimumab | “United States-licensed adalimumab (US-adalimumab)” PMID 33503313 ↗ Mar 2021 |
| Action | Inhibit | “adalimumab, a fully human monoclonal anti-TNF antibody” PMID 18716298 ↗ Aug 2008 |
| Modality | Monoclonal antibody | “adalimumab, a fully human monoclonal anti-TNF antibody” PMID 18716298 ↗ Aug 2008 |
| Route | Subcutaneous | “Patients who received ≥1 dose of adalimumab subcutaneously” PMID 30054164 ↗ Jul 2018 |
| Target | TNF | “adalimumab, a fully human monoclonal anti-TNF antibody” PMID 18716298 ↗ Aug 2008 |